1. Home
  2. ACRS vs SKLZ Comparison

ACRS vs SKLZ Comparison

Compare ACRS & SKLZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • SKLZ
  • Stock Information
  • Founded
  • ACRS 2012
  • SKLZ 2012
  • Country
  • ACRS United States
  • SKLZ United States
  • Employees
  • ACRS N/A
  • SKLZ N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • SKLZ EDP Services
  • Sector
  • ACRS Health Care
  • SKLZ Technology
  • Exchange
  • ACRS Nasdaq
  • SKLZ Nasdaq
  • Market Cap
  • ACRS 165.7M
  • SKLZ 136.4M
  • IPO Year
  • ACRS 2015
  • SKLZ N/A
  • Fundamental
  • Price
  • ACRS $1.93
  • SKLZ $7.46
  • Analyst Decision
  • ACRS Strong Buy
  • SKLZ Buy
  • Analyst Count
  • ACRS 9
  • SKLZ 1
  • Target Price
  • ACRS $9.25
  • SKLZ $14.00
  • AVG Volume (30 Days)
  • ACRS 800.9K
  • SKLZ 63.8K
  • Earning Date
  • ACRS 11-05-2025
  • SKLZ 11-06-2025
  • Dividend Yield
  • ACRS N/A
  • SKLZ N/A
  • EPS Growth
  • ACRS N/A
  • SKLZ N/A
  • EPS
  • ACRS N/A
  • SKLZ N/A
  • Revenue
  • ACRS $16,789,000.00
  • SKLZ $93,320,000.00
  • Revenue This Year
  • ACRS N/A
  • SKLZ $17.44
  • Revenue Next Year
  • ACRS N/A
  • SKLZ $12.03
  • P/E Ratio
  • ACRS N/A
  • SKLZ N/A
  • Revenue Growth
  • ACRS N/A
  • SKLZ N/A
  • 52 Week Low
  • ACRS $1.05
  • SKLZ $3.54
  • 52 Week High
  • ACRS $5.17
  • SKLZ $9.11
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 54.35
  • SKLZ 45.68
  • Support Level
  • ACRS $1.81
  • SKLZ $7.14
  • Resistance Level
  • ACRS $2.16
  • SKLZ $7.54
  • Average True Range (ATR)
  • ACRS 0.12
  • SKLZ 0.29
  • MACD
  • ACRS -0.03
  • SKLZ -0.08
  • Stochastic Oscillator
  • ACRS 34.29
  • SKLZ 24.25

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About SKLZ Skillz Inc.

Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.

Share on Social Networks: